Source: EP Vantage (originally posted 30 Sept 2011) Improved Gardasil? As the global debate about the cost effectiveness – and in some places ethics – of human papilloma virus (HPV) vaccines rumbles on, Merck & Co has been quietly working away on a 21,000 patient phase III program for an improved version of its blockbuster vaccine Gardasil. Relatively […]
Cancer Vaccines Poised to Reach $3 Billion in Sales by 2015
FALLS CHURCH, Va., April 19, 2011 /PRNewswire/ — Technology Catalysts International (TCI), leading global consultants to the pharmaceutical industry, announced that research on cancer trends and development has identified cancer vaccines as a viable treatment option for a variety of cancers that currently have ineffective treatments. The potential of the cancer vaccine market is forecast […]
